Correlates of protective immunity in poxvirus infection: Where does antibody stand?

Immunology and Cell Biology

Volumn 86, Issue 1, 2008, Pages 80-86

  Panchanathan, Vijay ^a,b   Chaudhri, Geeta ^b   Karupiah, Gunasegaran ^b  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b Biology and Environment   (Australia)

Author keywords

Antibody; Ectromelia virus; Immunity; Poxvirus; Secondary infection; Smallpox

Indexed keywords

INTERFERON; VIRUS ANTIBODY; VIRUS VACCINE;

ANTIBODY RESPONSE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INTERACTION; CLINICAL FEATURE; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; ECTROMELIA VIRUS; EFFECTOR CELL; GENETIC RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNITY; MONKEYPOX; NATURAL KILLER CELL; NONHUMAN; POXVIRUS; POXVIRUS INFECTION; REINFECTION; REVIEW; SECONDARY INFECTION; SMALLPOX VIRUS; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS GENE; VIRUS PATHOGENESIS;

ADOLESCENT; ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CHILD; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE COOPERATION; MICE; POXVIRIDAE; POXVIRIDAE INFECTIONS; RABBITS; RATS; SMALLPOX VACCINE;

ANIMALIA; ECTROMELIA VIRUS; MACACA; MONKEYPOX VIRUS; MUS; POXVIRIDAE; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 37849009631     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/sj.icb.7100118     Document Type: Review

References (78)

1. Fenner F, Henderson DA, Arita I, Jezek A, Ladnyi ID. Smallpox and Its Eradication. World Health Organization: Geneva, 1988.
2. Silvers MJ, Steptoe MM. Historical overview of vaccines. Prim Care 2001; 28: 685-695.
3. Fenner F. The Florey lecture, 1983. Biological control, as exemplified by smallpox eradication and myxomatosis. Proc R Soc Lond B Biol Sci 1983; 218: 259-285.
4. Diven DG. An overview of poxviruses. J Am Acad Dermatol 2001; 44: 1-16.
5. Horton R. Myths in medicine. Jenner did not discover vaccination. BMJ 1995; 310: 62.
6. Pead PJ. Benjamin Jesty: new light in the dawn of vaccination. Lancet 2003; 362: 2104-2109.
7. Stearn E, Stearn A. The Effect of Smallpox on the Destiny of the Amerindian. Bruce Humphries: Boston, Massachusetts, 1945.
8. Henderson DA. The looming threat of bioterrorism. Science 1999; 283: 1279-1282.
9. Moss B. Poxviridae: the viruses and their replication. In: Fields BN, David MK, Howley PM et al. (eds), Fields Virology. Lippincot-Raven Publishers: Philadelphia, 1996.
10. Takemura M. Poxviruses and the origin of the eukaryotic nucleus. J Mol Evol 2001; 52: 419-425.
11. Fenner F. Poxviruses. In: Fields BN, David MK, Howley PM, et al. (eds). Fields Virology. Lippincot-Raven Publishers: Philadelphia, 1996.
12. Harrison SC, Alberts B, Ehrenfeld E, Enquist L, Fineberg H, McKnight SL et al. Discovery of antivirals against smallpox. Proc Natl Acad Sci USA 2004; 101: 11178-11192.
13. Esposito JJ, Knight JC. Orthopoxvirus DNA: a comparison of restriction profiles and maps. Virology 1985; 143: 230-251.
14. Henderson DA. Bioterrorism as a public health threat. Emerg Infect Dis 1998; 4: 488-492.
15. Rao A. Smallpox. Kothari Book Depot: Bombay, 1972.
16. Downie AW, McCarthy K. The antibody response in man following infection with viruses of the pox group. III. Antibody response in smallpox. J Hyg (London) 1958; 56: 479-487.
17. Mack TM, Noble Jr J, Thomas DB. A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg 1972; 21: 214-218.
18. Sarkar JK, Mitra AC, Mukherjee MK. The minimum protective level of antibodies in smallpox. Bull World Health Organ 1975; 52: 307-311.
19. el-Ad B, Roth Y, Winder A, Tochner Z, Lublin-Tennenbaum T, Katz E et al. The persistence of neutralizing antibodies after revaccination against smallpox. J Infect Dis 1990; 161: 446-448.
20. Demkowicz Jr W, Littaua R, Wang J, Ennis F. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J Virol 1996; 70: 2627-2631.
21. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003; 171: 4969-4973.
22. Pütz MM, Alberini I, Midgley CM, Manini I, Montomoli E, Smith GL. Prevalence of antibodies to vaccinia virus after smallpox vaccination in Italy. J Gen Virol 2005; 86: 2955-2960.
23. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003; 9: 1131-1137.
24. Amara RR, Nigam P, Sharma S, Liu J, Bostik V. Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8T cells. J Virol 2004; 78: 3811-3816.
25. Esteban DJ, Buller RM. Ectromelia virus: the causative agent of mousepox. J Gen Virol 2005; 86: 2645-2659.
26. Bhatt PN, Jacoby RO. Mousepox in inbred mice innately resistant or susceptible to lethal infection with ectromelia virus. I. Clinical responses. Lab Anim Sci 1987; 37: 11-15.
27. Bhatt PN, Jacoby RO, Gras L. Mousepox in inbred mice innately resistant or susceptible to lethal infection with ectromelia virus. IV. Studies with the Moscow strain. Arch Virol 1988; 100: 221-230.
28. Fenner F. Mouse-pox (infectious ectromelia of mice): a review. J Immunol 1949; 63: 341-373.
29. Seet BT, Johnston JB, Brunetti CR, Barrett JW, Everett H, Cameron C et al. Poxviruses and immune evasion. Annu Rev Immunol 2003; 21: 377-423.
30. Smith VP, Alcami A. Expression of secreted cytokine and chemokine inhibitors by ectromelia virus. J Virol 2000; 74: 8460-8471.
31. Blanden RV, Gardner ID. The cell-mediated immune response to ectromelia virus infection. I. Kinetics and characteristics of the primary effector T cell response in vivo. Cell Immunol 1976; 22: 271-282.
32. Briody BA, Hauschka TS, Mirand EA. The role of genotype in resistance to an epizootic of mouse pox (ectromelia). Am J Hyg 1959; 63: 59-68.
33. Buller RM, Palumbo GJ. Poxvirus pathogenesis. Microbiol Rev 1991; 55: 80-122.
34. O'Neill HC, Brenan M. A role for early cytotoxic T cells in resistance to ectromelia virus infection in mice. J Gen Virol 1987; 68: 2669-2673.
35. Schell K. Studies on the innate resistance of mice to infection with mousepox. II. Route of inoculation and resistance; and some observations on the inheritance of resistance. Aust J Exp Biol Med Sci 1960; 38: 289-299.
36. Wallace GD, Buller RM. Kinetics of ectromelia virus (mousepox) transmission and clinical response in C57BL/6j, BALB/cByj and AKR/J inbred mice. Lab Anim Sci 1985; 35: 41-46.
37. Brownstein DG, Gras L. Differential pathogenesis of lethal mousepox in congenic DBA/2 mice implicates natural killer cell receptor NKR-P1 in necrotizing hepatitis and the fifth component of complement in recruitment of circulating leukocytes to spleen. Am J Pathol 1997; 150: 1407-1420.
38. Delano ML, Brownstein DG. Innate resistance to lethal mousepox is genetically linked to the NK gene complex on chromosome 6 and correlates with early restriction of virus replication by cells with an NK phenotype. J Virol 1995; 69: 5875-5877.
39. Brownstein DG, Bhatt PN, Gras L, Budris T. Serial backcross analysis of genetic resistance to mousepox, using marker loci for Rmp-2 and Rmp-3. J Virol 1992; 66: 7073-7079.
40. + T lymphocytes and macrophage subsets in the control of a generalized virus infection. J Virol 1996; 70: 8301-8309.
41. O'Neill HC, Blanden RV. Mechanisms determining innate resistance to ectromelia virus infection in C57BL mice. Infect Immun 1983; 41: 1391-1394.
42. Brownstein DG, Gras L. Chromosome mapping of Rmp-4, a gonad-dependent gene encoding host resistance to mousepox. J Virol 1995; 69: 6958-6964.
43. Fenner F. The clinical features and pathogenesis of mouse-pox (infectious ectromelia of mice). J Pathol Bacteriol 1948; 60: 529-552.
44. Chaudhri G, Panchanathan V, Buller RM, van den Eertwegh AJ, Claassen E, Zhou J et al. Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox. Proc Natl Acad Sci USA 2004; 101: 9057-9062.
45. Karupiah G, Fredrickson T, Holmes K, Khairallah L, Buller R. Importance of interferons in recovery from mousepox. J Virol 1993; 67: 4214-4226.
46. + T cells and CD40. Virology 1998; 240: 12-26.
47. Panchanathan V, Chaudhri G, Karupiah G. Interferon function is not required for recovery from a secondary poxvirus infection. Proc Natl Acad Sci USA 2005; 102: 12921-12926.
48. Ramshaw IA, Ramsay AJ, Karupiah G, Rolph MS, Mahalingam S, Ruby JC. Cytokines and immunity to viral infections. Immunol Rev 1997; 159: 119-135.
49. Parker AK, Parker S, Yokoyama WM, Corbett JA, Buller RM. Induction of natural killer cell responses by ectromelia virus controls infection. J Virol 2007; 81: 4070-4079.
50. Chaudhri G, Panchanathan V, Bluethmann H, Karupiah G. Obligatory requirement for antibody in recovery from a primary poxvirus infection. J Virol 2006; 80: 6339-6344.
51. Fang M, Sigal LJ. Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus. J Immunol 2005; 175: 6829-6836.
52. Kitamura D, Roes J, Kuhn R, Rajewsky K. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 1991; 350: 423-426.
53. Panchanathan V, Chaudhri G, Karupiah G. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J Virol 2006; 80: 6333-6338.
54. Jackson RJ, Maguire DJ, Hinds LA, Ramshaw IA. Infertility in mice induced by a recombinant ectromelia virus expressing mouse zona pellucida glycoprotein 3. Biol Reprod 1998; 58: 152-159.
55. Alcami A. Viralmimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 2003; 3: 36-50.
56. Alcami A, Smith GL. Soluble interferon-gamma receptors encoded by poxviruses. Comp Immunol Microbiol Infect Dis 1996; 19: 305-317.
57. Müllbacher A, Ebnet K, Blanden RV, Hla RT, Stehle T, Museteanu C et al. Granzyme A is critical for recovery of mice from infection with the natural cytopathic viral pathogen, ectromelia. Proc Natl Acad Sci USA 1996; 93: 5783-5787.
58. Mullbacher A, Hla RT, Museteanu C, Simon MM. Perforin is essential for control of ectromelia virus but not related poxviruses in mice. J Virol 1999; 73: 1665-1667.
59. Müllbacher A, Waring P, Tha Hla R, Tran T, Chin S, Stehle T et al. Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes. Proc Natl Acad Sci USA 1999; 96: 13950-13955.
60. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003; 101: 4500-4504.
61. Hebeis BJ, Klenovsek K, Rohwer P, Ritter U, Schneider A, Mach M et al. Activation of Virus-specific memory B cells in the absence of T cell help. J Exp Med 2004; 199: 593-602.
62. Williams RT, Dunsmore JD, Sobey WR. Fluctuations in the titre of antibody to a soluble antigen of myxoma virus in field populations of rabbits, Oryctolagus cuniculus (L.), in Australia. J Hyg (London) 1973; 71: 487-500.
63. Xu R, Johnson AJ, Liggitt D, Bevan MJ. Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 2004; 172: 6265-6271.
64. Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 2005; 11: 740-747.
65. Hiller G, Weber K. Golgi-derived membranes that contain an acylated viral polypeptide are used for vaccinia virus envelopment. J Virol 1985; 55: 651-659.
66. Appleyard G, Andrews C. Neutralizing activities of antisera to poxvirus soluble antigens. J Gen Virol 1974; 23: 197-200.
67. Law M, Smith GL. Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology 2001; 280: 132-142.
68. Gordon J, Mohandas A, Wilton S, Dales S. A prominent antigenic surface polypeptide involved in the biogenesis and function of the vaccinia virus envelope. Virology 1991; 181: 671-686.
69. Rodriguez JF, Janeczko R, Esteban M. Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus. J Virol 1985; 56: 482-488.
70. Galmiche MC, Goenaga J, Wittek R, Rindisbacher L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 1999; 254: 71-80.
71. Hsiao JC, Chung CS, Chang W. Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol 1999; 73: 8750-8761.
72. Wolffe EJ, Vijaya S, Moss B. A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology 1995; 211: 53-63.
73. r envelope protein of vaccinia virus is involved in cell fusion and forms covalently linked trimers. J Virol 1987; 61: 395-404.
74. Lai CF, Gong SC, Esteban M. The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals. J Virol 1991; 65: 5631-5635.
75. Hooper JW, Thompson E, Wilhelmsen C, Zimmerman M, Ichou MA, Steffen SE et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol 2004; 78: 4433-4443.
76. Heraud JM, Edghill-Smith Y, Ayala V, Kalisz I, Parrino J, Kalyanaraman VS et al. Subunit recombinant vaccine protects against monkeypox. J Immunol 2006; 177: 2552-2564.
77. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci USA 2003; 100: 9458-9463.
78. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004; 428: 182-185.